These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20726681)

  • 1. Studies recommending palivizumab restriction have serious deficiencies.
    Stewart DL
    J Manag Care Pharm; 2010 Sep; 16(7):509-11; author reply 511-2, discussion 512-4. PubMed ID: 20726681
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic disadvantages of palivizumab.
    Smith RA; Boon R
    Arch Dis Child; 2000 Apr; 82(4):336. PubMed ID: 10766708
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost minimisation of RSV prevention with palivizumab.
    Wills S; Simpson JH; Coutts J
    Arch Dis Child; 2006 Aug; 91(8):717. PubMed ID: 16861501
    [No Abstract]   [Full Text] [Related]  

  • 4. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
    [No Abstract]   [Full Text] [Related]  

  • 5. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
    Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
    Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.
    Resch B; Gusenleitner W; Nuijten MJ; Lebmeier M; Wittenberg W
    Clin Ther; 2008 Apr; 30(4):749-60. PubMed ID: 18498923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
    Kamal-Bahl S; Doshi J; Campbell J
    Arch Pediatr Adolesc Med; 2002 Oct; 156(10):1034-41. PubMed ID: 12361451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
    Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
    Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab (synagis): counting "costs" and values.
    Carter BS
    Pediatrics; 2000 Nov; 106(5):1168-9. PubMed ID: 11185071
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
    Suresh S; Schilling S; Dakin C; Harris MA
    J Paediatr Child Health; 2003 Nov; 39(8):637. PubMed ID: 14629536
    [No Abstract]   [Full Text] [Related]  

  • 18. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab (Synagis)--cohorting babies to reduce waste.
    Seeler RA; Schatz B
    Pediatrics; 1999 Nov; 104(5 Pt 1):1170-1. PubMed ID: 10577151
    [No Abstract]   [Full Text] [Related]  

  • 20. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis.
    Lee SR; Kwok KL; Ng DKK; Hon KL
    J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.